Indian Pen-G Makers Want Output Cut 75%

14 November 1997

India's Bulk Drug Manufacturers Association has told the government thatcompanies may have to cut production of penicillin-G to 75% of current output to stabilize prices. The proposed cut involves five major domestic manufacturers of penicillin-G, with total installed capacity of 5,310 MMU.

The Indian industry making penicillin-G has been hit by a slump in prices. The current average Indian market price for this product is about 475 rupees ($12.96) per MMU against the government's notified price of 1,025 rupees per MMU. Industry sources say the country has recently entered into making penicillin-G and has run into a series of problems. New plants bear a heavy burden on capital investment, and also have to pay relatively high interest costs. Moreover, India's climate is not conducive to the growth of penicillin-G culture, which involves high energy costs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight